ACTL6A and head and neck squamous cell carcinoma: As many RAS/RAF/MAPK inhibitors are clinically approved for use in other cancers52, it raises the possibility of clinical trials in HNSCC after stratifying tumors using hypoxia imaging or ACTL6A expression12,53.